A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
Ryan, Christine E., Brander, Danielle M., Barr, Paul M., Tyekucheva, Svitlana, Hackett, Liam R., Collins, Mary C., Fernandes, Stacey M., Ren, Yue, Zhou, Yinglu, McDonough, Mikaela M., Walker, Heather A., McEwan, Monica R., Abramson, Jeremy S., Jacobsen, Eric D., LaCasce, Ann S., Fisher, David C., Brown, Jennifer R., Davids, Matthew S.
Published in Leukemia (01.04.2023)
Published in Leukemia (01.04.2023)
Get full text
Journal Article
Inhibition of PRMT5 Increases Sensitivity to BH3 Mimetics in Aggressive B Cell Malignancies
Zhu, Fen, Ryan, Christine E., Hackett, Liam R., Collins, Mary C, Chong, Stephen Jun Fei, Davids, Matthew S.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
Ryan, Christine E., Lampson, Benjamin L., Tyekucheva, Svitlana, Hackett, Liam R., Ren, Yue, Shupe, Samantha J., Fernandes, Stacey M., Crombie, Jennifer L., Ng, Samuel, Kim, Austin I., Ahn, Inhye E., Weinstock, Matthew J, Pazienza, Samantha, Montegaard, Josie S., Patterson, Victoria, Jacobson, Caron A., LaCasce, Ann S., Armand, Philippe, Fisher, David C., Arnason, Jon E., Lo, Steve, Olszewski, Adam, Brown, Jennifer R., Davids, Matthew S.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article